Ipsen : Feedback from IR day and new guidance: expecting the worst but hoping for the best – Buy vs Neutral - Target price: € 124
>New guidance: sales € 3.2bn in 2022 and operating margin >32% - Ipsen has adjusted its guidance and set targets out to 2022 (sales of € 3.2bn and operating margin of 32%). This guidance appears conservative: i/ it factors in the arrival to market of generic versions of octreotide and lanreotide at, respectively, end-2020 and end-2021 (whilst the generics manufacturer Advanz has already suffered two rejections from the Finnish healthcare authorities with which it subm...Ipsen is global biotechnology specialty care company. Co. engages in research, development, manufacture and sale of pharmaceutical products for human healthcare. Co.'s product portfolio includes pharmaceutical products marketed around the world to specialists working in its targeted therapeutic areas (oncology, endocrinology, neurology and haematology). These products are specialist care drugs. Co. also markets products in other therapeutic areas including gastroenterology, cardiovascular and cognitive disorders. These products are primary care drugs. Co.'s brand names include Decapeptyl®, Somatuline®, Dysport®, Nutropin Aq®, Smecta®, Forlax®, Nisis®,Adrovance®, Exforge® and Adenuric®.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.